Protein phosphatase 2A (PP2A) is a critical human tumor-suppressor complex. A recently characterized PP2A inhibitor protein, namely cancerous inhibitor of PP2A (CIP2A), has been found to be overexpressed at a high frequency in most of the human cancer types. However, our understanding of gene expression programs regulated by CIP2A is almost absent. Moreover, clinical relevance of the CIP2A-regulated transcriptome has not been addressed thus far. Here, we report a high-confidence transcriptional signature regulated by CIP2A. Bioinformatic pathway analysis of the CIP2A signature revealed that CIP2A regulates several MYC-dependent and MYCindependent gene programs. With regard to MYCindependent signaling, JNK2 expression and transwell migration were inhibited by CIP2A depletion, whereas MYC depletion did not affect either of these phenotypes. Instead, depletion of either CIP2A or MYC inhibited cancer cell colony growth with statistically indistinguishable efficiency. Moreover, CIP2A depletion was shown to regulate the expression of several established MYC target genes, out of which most were MYC-repressed genes. CIP2A small-interfering RNA-elicited inhibition of colony growth or activation of MYC-repressed genes was reversed at large by concomitant PP2A inhibition. Finally, the CIP2A signature was shown to cluster with basal-type and human epidermal growth factor receptor (HER)2-positive (HER2 þ ) breast cancer signatures. Accordingly, CIP2A protein expression was significantly associated with basal-like (P ¼ 0.0014) and HER2 þ (Po0.0001) breast cancers. CIP2A expression also associated with MYC gene amplification (Po0.001). Taken together, identification of CIP2A-driven transcriptional signature, and especially novel MYC-independent signaling programs regulated by CIP2A, provides important resource for understanding CIP2A's role as a clinically relevant human oncoprotein. With regard to MYC, these results both validate CIP2A's role in regulating MYC-mediated gene expression and provide a plausible novel explanation for the high MYC activity in basal-like and HER2 þ breast cancers.
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Introduction
Previous work by Weinberg and colleagues has revealed that regardless of the vast number of different signaling proteins that have been linked to maintenance of tumorigenic phenotype, perturbation of only limited number of genetic elements is sufficient to induce cellular transformation in many different human cell types (Hahn et al., 1999; Rangarajan et al., 2004; Zhao et al., 2004) . Therefore, these common genetic elements could be considered as master regulators of cancer development and progression. One of the important conclusions of their study was that in addition to inhibition of two well-established tumor suppressors, namely p53 and Rb, inhibition of protein phosphatase 2A (PP2A) activity was also required for malignant transformation of normal human cells expressing activated HA-Ras and telomerase reverse transcriptase (Hahn et al., 1999; Rangarajan et al., 2004; Zhao et al., 2004) . Together with results of several follow-up studies (Chen et al., 2004; Zhao et al., 2004; Westermarck and Hahn, 2008) , these data have now established that PP2A is one of the critical human tumor suppressors (Mumby, 2007; Westermarck and Hahn, 2008; Eichhorn et al., 2009) . PP2A is a trimeric phosphatase complex that accounts for a significant fraction of all cellular serine/ threonine phosphatase activity. The PP2A complex consists of a catalytic C subunit (PP2Ac), a scaffolding A subunit (PR65) and various regulatory B subunits (Janssens et al., 2008; Eichhorn et al., 2009 ). PP2A activity is regulated by its complex composition and by post-translational modifications of its subunits (Janssens et al., 2008; Eichhorn et al., 2009) . A third level of regulation of PP2A activity is interaction of PP2A dimers and trimers with endogenously expressed PP2A-interacting proteins (Westermarck and Hahn, 2008; Virshup and Shenolikar, 2009 ). Nevertheless, very little is known about the mechanisms regulating PP2A complex composition and/or its activity in mammalian cells, or the clinical relevance of PP2A regulation in human malignancies.
With regard to the mechanisms by which PP2A activity may be inhibited in human malignancies, we recently identified a novel protein-protein interaction partner for PP2A (Junttila et al., 2007) . On the basis of the PP2A-inhibiting activity of this protein and its cancer-selective expression, it was designated as the cancerous inhibitor of PP2A (CIP2A) (Junttila et al., 2007) . CIP2A depletion results in inhibition of malignant cell growth and inhibition of tumor growth in mouse xenograft models (Junttila et al., 2007; Come et al., 2009) . CIP2A is overexpressed in most major solid human cancer types, including head and neck squamous cell carcinomas as well as gastric, esophageal, breast, colon, lung and prostate cancer (Junttila et al., 2007; Li et al., 2008; Come et al., 2009; Khanna et al., 2009; Dong et al., 2010; Katz et al., 2010; Qu et al., 2010; Vaarala et al., 2010) . Strikingly, with the exception of breast cancer, in which 40% of patient samples overexpress CIP2A (Come et al., 2009) , all other studied human cancer types have CIP2A overexpression in 65-90% of patient samples. Moreover, CIP2A expression predicts poor patient prognosis in certain gastric cancer subtypes and in non-small cell lung cancer (Khanna et al., 2009; Dong et al., 2010) . In breast cancer, CIP2A expression correlates with disease aggressiveness and in prostate cancer with a high Gleason's score (Come et al., 2009; Vaarala et al., 2010) . Taken together, these studies have firmly established CIP2A as a novel, clinically relevant human oncoprotein.
The transcription factor MYC is one of the most studied and important human oncoproteins (Meyer and Penn, 2008) . In breast cancer, MYC activity is closely linked to the basal-like and the human epidermal growth factor receptor (HER)2-positive (HER2 þ ) subtypes (Xu et al., 2010) . The MYC protein is overexpressed in B45% of breast tumors, whereas MYC gene amplification is observed only in B15% of tumors and mRNA overexpression in 22-35% of breast cancers (Xu et al., 2010) . These results suggest involvement of post-translation regulation in MYC protein overexpression in breast cancer. However, the mechanisms that promote MYC protein expression and activity in breast cancer are poorly understood. In cultured cells, inhibition of PP2A, either by viral small-t antigen or CIP2A expression, results in MYC protein stabilization (Junttila et al., 2007) . Accordingly, several recent studies have confirmed that depletion of CIP2A in human cancer cell lines results in MYC protein degradation (Junttila et al., 2007; Come et al., 2009; Dong et al., 2010) . However, it has not yet been determined whether CIP2A-mediated PP2A regulation indeed mediates CIP2A's effects on MYC expression and cancer cell proliferation. Moreover, the MYC dependency of gene expression profiles and cellular phenotypes regulated by CIP2A has not yet been thoroughly addressed. As CIP2A-regulated transcriptional programs have not been characterized thus far, it has not been possible to address whether the functional effects of CIP2A on MYC are linked to certain types of cancer.
In this study, we report the first global transcriptome analysis of the CIP2A function. Bioinformatic analysis of its transcriptional signature suggested that CIP2A promotes both MYC-dependent and MYC-independent signaling. Accordingly, we demonstrate a previously unknown MYC-independent role for CIP2A in regulating JNK2 gene expression and transwell cell migration. With regard to MYC-dependent CIP2A roles, we show that CIP2A regulates the expression of previously identified direct MYC target genes. However, the CIP2A signature also reveals several previously unidentified MYC-regulated genes. Importantly, we verify that CIP2A's effects on both MYC expression and colony growth are reversed by concomitant PP2A inhibition. Finally, we demonstrate that the CIP2A signature clusters together with basal-like and HER2 þ breast cancer signatures and that the CIP2A protein expression is significantly associated with both of these breast cancer subtypes. CIP2A is also shown to promote MYC target gene expression in basal-like breast cancer cells. Thus, our results indicate that the CIP2A signature could be useful in identification of both novel surrogate markers and therapy targets in MYC-driven basal-like and HER2 þ breast cancers.
Results
Characterization of the CIP2A-driven transcriptional signature To characterize the transcriptional signature driven by CIP2A in cancer cells, HeLa cells were transfected with either scrambled or specificity-validated CIP2A smallinterfering RNA (siRNA) (Junttila et al., 2007) , and genome-wide gene expression profiles were analyzed 3 and 5 days after transfection using the Illumina platform. We have previously used HeLa cells in diverse experiments to study the function of CIP2A, and the effects of CIP2A in HeLa cell growth both in vitro and in vivo, as well as in MYC expression are well established. Thus, HeLa cells were also chosen as the model cell line to identify CIP2A-regulated transcriptional signature. Downregulation of CIP2A protein levels by siRNA transfection was confirmed by western blotting at both 3 and 5 day time points (Figure 1a) . The microarray raw data were normalized to quartiles, and the fold change for each CIP2A/scrambled sample pair was calculated. Except certain genes, depletion of CIP2A did not induce drastic changes in gene expression profiles. Instead, subtle expression level changes for the same genes were observed in repeat experiments. Thus, to create a high-confidence CIP2A transcriptional signature, the experiment was repeated five times and only genes that surpassed the threshold of 1.3 in all five replicate sample pairs were included in the final signature. On the basis of these strict criteria, the CIP2A-driven transcriptional signature consists of 134 different genes (Supplementary Table 1 ). Of these, 112 genes were seen only at day 3, and 9 genes were seen only at day 5, whereas 13 of the total 134 signature genes were regulated at both time points (Figure 1b) . The heatmap shown in Figure 1c depicts expression levels of the 50 top regulated genes at day 3 and all differentially regulated genes at day 5. The remaining signature genes and their regulation by CIP2A are shown in Supplementary Table 1 .
To validate CIP2A-dependent regulation of signature genes, we examined the mRNA expression levels of 12 randomly chosen signature genes in CIP2A-depleted HeLa cells using reverse transcriptase (RT)-qPCR ( Figure 1d ). For this purpose, we used two previously published siRNA sequences against CIP2A (Junttila et al., 2007) . The specificity of one of these siRNAs has been validated by an add-back rescue experiment (Junttila et al., 2007) . In HeLa cells, all of the quantitative RT-PCR-tested genes were regulated similarly as on the microarray by both of the tested siRNAs (Figure 1d and Supplementary Figure 1A) . The signature was further validated in MCF7 breast cancer, and AGS gastric cancer cell line and all 9/12 and 8/12 signature genes that were expressed in these cells at detectable level, respectively, were similarly regulated by CIP2A siRNA as in HeLa cells (Supplementary Figures 1B and C) . Thus, these results verify that the CIP2A transcriptional signature presented here consists of genes that are CIP2A regulated with high confidence in human cancer cells.
Network analysis of the CIP2A signature genes To characterize the cellular signaling pathways in which CIP2A signature genes are involved, we conducted ingenuity pathway analysis (Sigma-Aldrich). On the basis of the day-3 signature, ingenuity pathway analysis revealed a total of 7 networks that were altered significantly as indicated by ingenuity score 415 (Table 1 ). The most significantly altered pathway at day 3 consisted of several genes that have been previously linked to cellular migration (Table 1, Figure 2a ). At day 3, MYC was found in network number 7, as ranked by the ingenuity score (Table 1) . In turn, the analysis of the day-5 signature yielded only two Identification of the CIP2A-regulated transcriptome M Niemelä et al ingenuity networks that were significantly associated with the signature. Here, MYC was found in the most significantly altered network, that is, network number 1 ( Figure 2b , Table 1 ). As expected, due to the posttranslational mechanism by which CIP2A regulates MYC (Junttila et al., 2007) , CIP2A siRNA inhibited Figures 2A and B) . A graphical illustration of all networks significantly linked to the signature (Table 1) is shown in Supplementary Figures 3 and 4 . To further substantiate pathway analyses, we also analyzed CIP2A signature genes with the gene set enrichment analysis (GSEA) database (http://www. broadinstitute.org/gsea/). Interestingly, genes upregulated by CIP2A depletion were associated with 'genes downregulated by MYC, according to the MYC Target Gene Database', both in the 3-and the 5-day signatures. The P-values for the association were 5.58e À9 and 7.77e À7 , respectively. Moreover, related to the cellular migration pathway linked to CIP2A signature by ingenuity analysis, GSEA also revealed association of focal adhesion phenotype with the CIP2A signature (P-value ¼ 4.8e À5 ).
CIP2A promotes MYC-independent transwell migration and JNK2 expression in HeLa cells
To explore the functional consequences of CIP2A depletion with the help of the CIP2A signature, we next analyzed the molecular and cellular functions of the signature genes. On the basis of the day-3 signature, CIP2A depletion had the most significant effect on cellular movement with 28 genes affected (P ¼ 1.22E-06 to 1.33E-02) (Table 2) . Alternatively, at day 5, the most altered function was cellular growth and proliferation, with 12 genes affected (P ¼ 5.61E-08 to 1.48E-02) ( Table 2) . A strong association of the day-3 signature with genes that have established functions in cellular migration and movement ( Figure 2a , Tables 1 and 2 ) led us to further study the potential role for CIP2A in these phenotypes. We did not observe significant effects of CIP2A depletion on scratch wound healing or adhesion of HeLa cells (Supplementary Figures 5A and B) . However, CIP2A depletion did significantly inhibit transwell migration of HeLa cells in a Boyden chamber assay ( Figure 3a , upper panel, and Supplementary Figure 5C ). As already suggested by the ingenuity analysis, the migration-promoting function of CIP2A does not seem to be linked to CIP2A's role in regulating MYC because MYC inhibition through siRNA transfection did not inhibit transwell migration (Figure 3a) . The MYC-independent effects on the transwell migration of HeLa cells are consistent with previously published observations by Cappellen et al. (2007) . Importantly, even though CIP2A seemed to regulate cell migration by MYC-independent mechanisms, the migration defect in CIP2A siRNA-transfected cells was rescued by subsequent treatment of cells with PP2A inhibitor okadaic acid (Figure 3b ). Therefore, these results identify transwell migration of HeLa cells as MYC independent but PP2A-dependent cellular phenotype regulated by CIP2A.
To further validate the MYC-independent functions of CIP2A, we focused on regulation of the MAPK9 (JNK2) gene, which was linked to MYC-independent cellular movement functions based on the ingenuity analysis (Supplementary Table 2 ). JNK2 has also previously been implicated as the cancer-promoting isoform of the JNK family of mitogen-activated protein kinases (Mathiasen et al., 2011) . CIP2A depletionelicited downregulation of JNK2 mRNA and protein levels was verified by RT-qPCR and western blot analysis, respectively (Figures 3c and d) . However, we found that JNK2 mRNA expression was not inhibited by MYC siRNA, even though MYC depletion inhibited the expression of the validated MYC target genes, E2F2 and NCL (nucleolin) (Figure 3e ).
On the basis of these results, we identified novel MYC-independent functions for CIP2A in promoting transwell migration and JNK2 expression in HeLa cells.
CIP2A, MYC, PP2A and proliferation
On the basis of the network analysis, cellular growth and proliferation pathways related to CIP2A signature genes were associated with MYC (Tables 1 and 2 ). To clarify the MYC dependency of CIP2A-mediated proliferation regulation, we performed a colony-formation assay with either CIP2A or MYC siRNA-transfected HeLa cells. As shown in Figures 4a and b, CIP2A and MYC siRNAs inhibited colony growth of HeLa cells with statistically indistinguishable efficiency. These results suggest that MYC contributes to the CIP2A-mediated stimulation of HeLa cell colony growth. Recently, several independent studies have demon- Identification of the CIP2A-regulated transcriptome M Niemelä et al strated that CIP2A inhibits cellular PP2A activity (Junttila et al., 2007; Chen et al., 2010; Guenebeaud et al., 2010) . Moreover, in HeLa cells used for this study, siRNA-mediated CIP2A inhibition induced cellular PP2A activity (data not shown). To define the role of PP2A in the CIP2A-mediated regulation of MYC expression, we tested whether the simultaneous siRNA-based depletion of certain PP2A B subunits could rescue the downregulation of MYC protein levels in CIP2A-depleted cells. Out of altogether five B subunits screened, we could identify two proteins (B55a and B56b) the depletion of which invariably and significantly reversed inhibition of MYC protein expression (Figure 4c ). Efficient depletion of these B subunits was controlled by RT-PCR (Supplementary Figure 6) . Importantly, depletion of these same B subunits (B55a and B56b) also almost completely reversed CIP2A siRNA-elicited inhibition of HeLa cell colony growth (Figure 4c ). Taken together, these findings validate the signature-based prediction that the proliferation effects of CIP2A-mediated PP2A inhibition are mediated by MYC. Moreover, these results identify PP2A complexes containing the B subunits B55a, or B56b being involved in MYC and proliferation regulation by CIP2A. Identification of the involvement of several PP2A B subunits, including B55a, in the negative regulation of MYC protein expression is consistent with recently published findings (Arnold and Sears, 2006; Ben-Israel et al., 2008; Sablina et al., 2010) .
Identification of MYC-regulated genes from the CIP2A signature Results above link CIP2A and MYC together in the regulation of cancer cell proliferation. Next, the CIP2A signature was used to assess the MYC dependency of CIP2A's effects on regulation of gene expression. To this end, we studied how the 12 RT-PCR-validated CIP2A signature genes shown in Figure 1d were regulated by MYC siRNA. Among the 12 studied genes (Figure 5a ), 4 are known MYC targets (PLAUR, SERPINE2, SLC22A4 and CAV1) (http://www.myccancer-gene.org). Moreover, out of these established MYC targets, SLC22A4 and SERPINE2 have been demonstrated to directly bind MYC at their promoters (Fernandez et al., 2003; Li et al., 2003) . As shown in Figure 5a , the expression of PLAUR, SERPINE2 and SLC22A4 was upregulated after MYC depletion (M), and as was already shown in Figure 1d , CIP2A inhibition (C) also stimulated the expression of these genes. Furthermore, by analyzing a panel of human breast-derived cell lines for their expression levels of the validated MYC targets, PLAUR, SERPINE2 and SLC22A4, we identified 15 cell lines in which inverse Identification of the CIP2A-regulated transcriptome M Niemelä et al correlation between the expression of CIP2A (KIAA1524) and at least 2 out of 3 of these genes was observed (Figure 5b ). These results indicate that CIP2A-mediated regulation of these MYC target genes is not restricted to conditions in which CIP2A expression has been modulated by siRNA. Among the CIP2A signature genes that were not previously known to be MYC regulated, an additional five genes (FAP, SAT1, COL8A1, LAMA1 and MFAP5) were similarly affected by both CIP2A and MYC depletion (Figure 5a ). Taken together, these data demonstrate that 67% (8/12) of the examined CIP2A signature genes are similarly regulated by both CIP2A and MYC. As shown in Figure 5c , CIP2A and MYC siRNAs also similarly regulated the expression of four prototypical MYC target genes: p15, GADD45A, NCL and E2F2. Consistent with the observation that the majority of CIP2A signature genes were induced in CIP2A-depleted cells (Figure 1c, Supplementary Table 1) , we also found that the MYC-repressed genes (p15 and GADD45A) were more affected than were the MYC-activated genes (NCL and E2F2) (Figure 5c ). However, CIP2A depletion did significantly inhibit the activity of the MYC/MAX-sensitive minimal E-box promoter (Figure 5d ), demonstrating that CIP2A also promotes the function of activating MYC complexes. As a control, CIP2A depletion did not affect p53-regulated transcriptional activity (Figure 5d ).
As pointed out above, out of a total of 134 differently regulated genes by CIP2A, 91 were upregulated and 43 were downregulated in response to CIP2A depletion ( Figure 1c and Supplementary Table 1) . Moreover, the GSEA and the results shown in Figure 5a , together with more robust effects of CIP2A depletion on MYCrepressed genes (Figure 5c ), clearly indicate that CIP2A is predominantly involved in regulation of MYCmediated gene repression. On the other hand, our data show that CIP2A effects on MYC protein expression are mediated by PP2A activity (Figure 4c ). To further strengthen the functional links between CIP2A, PP2A and MYC, we evaluated whether CIP2A's effects on regulation of CIP2A-and MYC-repressed genes ( Figure 5a ) were PP2A dependent. As shown in Figure 5e , CIP2A siRNA-elicited induction of all CIP2A and MYC repressed genes from Figure 5a , except that of COL8A1, was reversed by simultaneous inhibition of either one or both of the PP2A B subunits B55a and B56b. Interestingly, B-subunit depletion also Taken together, these data demonstrate that the CIP2A signature contains validated MYC target genes and that CIP2A is predominantly involved in regulation of MYC-repressed genes. Furthermore, it was shown that CIP2A's effects on gene expression are at large mediated by PP2A.
Clinical relevance of the CIP2A signature in breast cancer Both CIP2A and MYC are implicated in human breast cancer development (Come et al., 2009; Xu et al., 2010) . Therefore, to assess the clinical relevance of the CIP2A-regulated transcriptome, we compared the CIP2A signature with two published breast cancer microarray signatures (Miller et al., 2005; Enerly et al., 2011) . By comparing the CIP2A signature with recently published mRNA expression profiles from 114 human breast cancers (Enerly et al., 2011) , we found that the CIP2A signature clustered all cancers to four major subgroups, out of which the first one was almost exclusively enriched with both basal-like and HER2 þ (ERBB2) breast cancer subtypes (Figure 6a) . Importantly, similar clustering of both basal-like and HER2 þ subtypes was also found when the CIP2A signature was compared with the Miller data set (Miller et al., 2005) (Supplementary Figure 7) .
The association of the CIP2A signature with both basal-like and HER2 þ breast cancers suggests that CIP2A might have a profound role in these disease subtypes. To further support these conclusions, CIP2A protein expression was evaluated by immunohistochemical staining in a series of 1028 human breast cancer samples (Joensuu et al., 2003) . In accordance with previously published data (Come et al., 2009) , CIP2A was found to be expressed in 45% of all breast cancer samples studied (Figure 6b) , and its expression correlated with higher tumor grade (data not shown). Moreover, in accordance with the data shown in Figure 6a , CIP2A was overexpressed significantly more frequently in basal-like and HER2 þ breast cancers than in all breast tumors analyzed (Figure 6b and Supplementary Figure 8A) .
To assess whether CIP2A expression and MYC amplifications associate, the same breast tumor material was analyzed for MYC amplifications by fluorescence in situ hybridization (FISH) assay. On the basis of a recent meta-analysis of 29 studies, it was concluded that the average frequency of MYC amplification in breast tumors, which was defined as a two-fold increase in gene copy number, was 15.7% (Deming et al., 2000; Xu et al., 2010) . In our material of 144 representative samples, the frequency of MYC amplification was 18.1% ( Figure 6c ) (a representative image of MYC amplification is shown in Supplementary Figure 8B) . Interestingly, rather than being mutually exclusive, MYC amplification significantly associated with CIP2A expression (Figure 6c) .
The association of CIP2A with basal-like breast cancers also became evident from the analysis of CIP2A mRNA expression levels across 40 breast cancer cell lines. Out of all cell lines examined, the highest CIP2A mRNA expression was found in the BRCA1-mutant cell line, HCC1937, whereas the lowest expression was detected in the non-cancerous, immortalized mammary epithelial cell line, MCF10A (Figure 6d) . Importantly, all top seven CIP2A expressing cell lines were of basallike origin (Figure 6d) . We have previously demonstrated that CIP2A promotes MYC expression, anchorage-independent proliferation and xenograft tumor growth of basal-like MDA-MB-231 breast cancer cells (Come et al., 2009) . To assess whether CIP2A promotes MYC-mediated gene expression in basal-like cells, the expression of MYC-regulated signature genes (Figure 5a ) in CIP2A siRNA-transfected MDA-MB-231 cells was examined. The expression of all of the MYC-regulated signature genes, except one (LAMA1), was detectable in MDA-MB-231 cells. Furthermore, all expressed genes were similarly regulated in CIP2A-depleted MDA-MB-231 cells as were observed in both CIP2A-and MYCdepleted HeLa cells (Figures 6e and 5a) .
Taken together, these results demonstrate a clinical association of the CIP2A signature with basal-like and HER2 þ breast cancers. Moreover, MYC amplification and CIP2A overexpression are not mutually exclusive in human breast cancers. Therefore, overexpression of CIP2A provides a novel explanation for high MYC protein expression in basal-like and HER2 þ breast cancers in which the MYC gene transcription is enhanced either because of increased MYC promoter activity or gene amplification (Alles et al., 2009; Chandriani et al., 2009; Xu et al., 2010) .
Discussion
In this study, we present the first global signaling analysis of the function of the PP2A inhibitor protein, CIP2A, in human cancer cells. CIP2A is an independently validated PP2A inhibitor protein and a clinically relevant human oncoprotein. Therefore, it was hypothesized that characterization of the CIP2A-regulated transcriptome would reveal novel insights into the signaling mechanisms downstream of oncogenic PP2A inhibition. To circumvent the acknowledged limitations in the repeatability of published microarray results (Ioannidis et al., 2009) , the reported CIP2A signature consists only of genes regulated by CIP2A depletion in all five independent sample pairs. All tested signature genes were shown by quantitative RT-PCR to be regulated by CIP2A in four cancer cell lines (Figures 1d and 6e and Supplementary Figures 1B and C) in which CIP2A has previously been shown to be overexpressed (Junttila et al., 2007; Come et al., 2009; Khanna et al., 2009; Choi et al., 2011) . Thus, we consider the reported CIP2A signature to be a reliable representation of the transcriptional program driven by CIP2A in human cancer cells.
Pathway-level analysis of the signature genes indicated that CIP2A regulates both MYC-independent and MYC-dependent signaling. With regard to MYCindependent CIP2A functions, we discovered a novel role for CIP2A in promoting JNK2 expression and transwell migration in HeLa cells, whereas MYC depletion did not affect either of these phenotypes (Figure 3) . Moreover, among the RT-PCR-validated signature genes, we identified genes that were regulated by CIP2A, but not by MYC depletion (Figure 5a ). It is anticipated that further analysis of MYC-independent genes included in the CIP2A signature will reveal novel mechanisms by which CIP2A regulates cell behavior independently of its function in MYC stabilization. p<0.001 Identification of the CIP2A-regulated transcriptome M Niemelä et al
Regardless of the established role for CIP2A in regulating MYC expression (Junttila et al., 2007; Come et al., 2009; Dong et al., 2010) , thus far, the contribution of CIP2A to MYC-mediated gene expression regulation has not been analyzed. Here, pathway analysis of the CIP2A signature genes revealed significant association of the day-5 CIP2A signature with MYC-associated signaling (Figure 2) . Moreover, RT-PCR analysis verified that CIP2A depletion significantly modulated the expression of four direct MYC target genes (SLC22A4, SERPINE2, p15 and GADD45A). In addition, we identified several novel MYC-regulated genes from the CIP2A signature (Figure 5a ). Taken together, the results of this study validate the functional role of CIP2A in regulating MYCmediated cellular signaling output.
Transcriptional signatures are being used to classify cancer subtypes and for patient stratification in cancer therapy trials. Here, we show that among the different breast cancer subtypes, the CIP2A-regulated transcriptome clustered most clearly together with basal-like and HER2 þ breast tumors (Figure 6a) . Moreover, the CIP2A protein was found to be predominantly overexpressed in both of these breast cancer subtypes (Figure 6b ). On the other hand, in breast cancer cell lines, the highest CIP2A expression levels were detected in cells of basal-like origin (Figure 6d ). Taken together, these results strongly indicate that CIP2A is closely linked to the basal-like breast cancer subtype and is also involved in HER2 þ cancers. On the basis of our results, it is clear that further verification of the value of CIP2A signature genes and CIP2A itself, in terms of more a precise classification and treatment stratification of breast cancer patients, deserves further attention.
It has been suggested that post-translational MYC protein stabilization may have an important role in MYC-mediated oncogenic functions in breast cancer (Xu et al., 2010) . However, the mechanisms by which MYC might be stabilized in basal-like and HER2 þ breast cancers have not been identified as yet. The strong expression of the MYC-stabilizing protein CIP2A and clinical association of its signature in basal-like and HER2 þ breast cancers identified in this study provides a novel, plausible explanation for the increased MYC protein levels and activity in these breast cancer subtypes. Association of MYC amplification and CIP2A expression in breast cancer is another novel finding of this study and suggests that inhibition of bidirectional positive feedback loop between MYC and CIP2A (Khanna et al., 2009; Mannava et al., 2011) could be an attractive therapeutic target in breast cancers in which these two oncogenic alterations exist. Moreover, it is plausible that further functional analysis of MYC-dependent CIP2A signature genes will reveal novel mechanisms by which these two oncoproteins together promote disease progression in basal-like and HER2 þ breast cancers. Furthermore, our current results, together with the demonstrated tumor growth-promoting activity of CIP2A in MDA-MB-231 cells (Come et al., 2009) , indicate that either CIP2A or CIP2A signature genes identified herein present as attractive novel targets for cancer therapeutics in these breast cancer subtypes.
In conclusion, we have identified and validated a CIP2A-driven transcriptional signature. Pathway analysis of these signature genes revealed both MYCdependent and MYC-independent functions of CIP2A. Importantly, our data both validate the role for CIP2A in regulating established MYC target genes and identify novel MYC-regulated genes. We also provide the first demonstration that CIP2A's effects on cancer cell behavior are mediated by PP2A complexes. Importantly, the clinical significance of this study is highlighted by a signature-associated identification of the linkage between basal-like and HER2 þ breast cancers and CIP2A. Taken together, it is expected that the identified signature will be an important resource for understanding how the emerging human oncoprotein CIP2A exerts its oncogenic functions in human malignancies. Finally, it is tempting to speculate that this signature may help in future patient stratification methods for current adjuvant therapies and in future for MYC-and/or CIP2A-targeted therapies.
Bioinformatic analysis
Identification of signaling networks and biological functions associated with CIP2A signature genes was conducted by ingenuity pathway analysis (Ingenuity Systems, Redwood City, CA, USA) according to their standard procedures.
To identify association of the CIP2A signature with human breast cancer subtypes, we extracted preprocessed publicly available breast cancer gene expression profiling data sets with breast cancer molecular subtype annotation from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus. These data sets can be accessed through series accession numbers GSE19783, GSE4922 and GSE1456. GSE19783 is based on Agilent microarray platform (Agilent, Santa Clara, CA, USA), whereas GSE4922 and GSE1456 are both based on Affymetrix microarray platforms (Affymetrix, Santa Clara, CA, USA; U133 A and B arrays). Owing to the complexity in combining data from two different microarray platforms, we decided to perform the analysis in each platform type separately. U133A and U133B chips were preprocessed separately using the R language (R Development core team, Vienna, Austria) and the RMA method implemented in the Bioconductor (Gentleman et al., 2004) package affy. Alternative CDF files mapping Affymetrix probes directly to Ensembl gene ids were used in preprocessing (Dai et al., 2005) . Data from U133A and U133B were combined by calculating the medians of genes appearing on both array types. The tumors were classified into different breast cancer subtypes as described previously in the original articles (Miller et al., 2005; Enerly et al., 2011) . We performed hierarchical clustering of the 134 CIP2A signature genes across 114 human breast tumors from GSE19783 and across 251 breast tumors from GSE4922 and GSE1456.
To analyze CIP2A expression in human breast-derived cell lines, gene expression data of 39 human breast cancer cell lines were extracted from the National Cancer Institute's cancer Bioinformatics Grid (caBIG). The data were pre-processed using R and RMA method implemented aroma.affymetrix package. The data were originally generated using Affymetrix GeneChip U133 Plus 2.0 arrays. On the basis of these data, a heatmap of the expression difference of CIP2A (KIAA1524), PLAUR, SERPINE2 and SLC22A4 across all the breast cancer cell lines was also generated.
Breast cancer patient material Nationwide population-based breast cancer series was constructed as described in detail elsewhere (Joensuu et al., 2003) . Inclusion criteria for subjects based on clinical data are presented in Supplementary Materials and Methods. Representative tumor samples for CIP2A immunohistochemistry were available for 1228 subjects, in whom molecular breast cancer subtypes were successfully defined for 1028 tumors. These 1028 tumors were entered into the study. Formalin-fixed, paraffin-embedded tumor samples were collected from hospital archives. Representative tumor regions were defined from tumor samples using hematoxylin and eosin staining, and tissue microarray blocks were constructed from those tumors using 0.6 mm diameter needle. Permission to use tissues for research purposes was provided by the Ministry of Social Affairs and Health, Finland (permission 123/08/97).
Immunohistochemistry
Before immunostaining of CIP2A, tissue microarray sections were deparaffinized and rehydrated, and endogenous peroxidase activity in tissues was blocked using 3% hydrogen peroxide. Antigen retrieval was carried out in Tris-EDTA buffer (pH 9.0, 10 mM Tris, 1 mM EDTA) by heating sections in water bath (98 1C, 30 min). The CIP2A antibody was diluted in PowerVision blocking solution (1:5000), and incubated on sections overnight at 4 1C. The primary antibody was detected using PowerVision þ Poly-HRP-histostaining kit (DVPB þ 110DAP, Technologies Co., Daly City, CA, USA) following the manufacturer's protocol. CIP2A expression was graded based on cytoplasmic staining intensity as negative or positive. Immunostainings and gradings for ER, PgR, HER2, EGFR and CK5 were performed as described in detail earlier (Sihto et al., 2008) . Cancers were grouped into five molecular subtype based on their expression profile (Luminal A: ER þ and/or PgR þ , HER2À; Luminal B: ER þ and/or PgR þ , HER2þ ; HER2: ERÀ and PgRÀ, HER2 þ ; Basal-like: ERÀ, PgRÀ, HER2À, CK5þ and/or EGFR þ : Non-expressor: all five markers negative).
FISH analysis
The MYC copy number was assessed from 436 out of 1028 breast cancers using FISH. A total of 292 samples were rejected from analysis because of missing tumor tissue on tissue microarray slides or poor FISH quality, leaving total of 144 samples into series. Samples were hybridized with Vysis LSI C-MYC (8q24.12-q24.13) SpectrumOrange Probe and centromeric CEP 8 (D8Z2) probe according to the manufacturer's instructions (Abbot Molecular, Des Plaines, IL, USA). Ratio of orange-labeled MYC and green-labeled centromere 8 FISH signals were assessed within tumor cells using Â 1000 magnification. A signal ratio two or more were considered to represent MYC amplification. If 410% of tumor cells were estimated to contain MYC amplification, MYC/centromere 8 signal ratio was assessed only in cells with amplification. Samples were analyzed using Zeiss Axioplan 2 fluorescence microscope and images were acquired with AxioVision software (Carl Zeiss MicroImaging GmbH, Jena, Germany).
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